Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Ashish Bhatia MD, FAAD
Ashish C. Bhatia MD, FAAD Associate Editor
Christen Mowad MD
Christen Maria Mowad MD Advisory Board
Robert Brodell MD, FAAD
Robert T. Brodell MD, FAAD Editor-in-Chief
See All Experts
featured
Published in Dermatology

Expert Opinion / Commentary · December 02, 2014

2014 Top Stories in Dermatology: Ten Dermatology Tips that Changed My Clinical Practice in 2014

Robert Brodell MD, FAAD

 

 Save  Recommend
 Share

Additional Info

  1. Sandborn WJ, Casink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367(16):1519-1528.
  2. Heetun ZS, Keegan D, O’Donoghue D, Doherty GA. Report of successful use of ustekinumab in Crohn’s disease refractory to three anti-TNF therapies. Ir J Med Sci. 2014;183(3):507-508.
  3. Almugairen N, Hospital V, Bedane C, et al. Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol. 2013;69(4):583-588.
  4. Reguiai Z, Tabary T, Maizières M, Bernard P. Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up. J Am Acad Dermatol. 2012;67(4):623-629.
  5. Hall RP, Fairley J, Woodley D, et al. A multi-centered randomized trial of the treatment of pemphigus vulgaris patients with infliximab and prednisone compared to prednisone alone [published online ahead of print August 13, 2014]. Br J Dermatol. doi: 10.1111/bjd.13350.
  6. Taib A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial [published online ahead of print September 16, 2014]. Br J Dermatol. doi: 10.1111/bjd.13408.
  7. Cosulich M, Molenda MA, Mostow E, et al. Minimal incision extraction of lipomas [published online ahead of print October 22, 2014]. JAMA Dermatol. doi: 10.1001/jamadermatol.2014.3234.
  8. Gathings R, Reddy R, Santa Cruz D, Brodell RT. Gadolinium-associated plaques: a new, distinctive clinical entity [published online ahead of print November 12, 2014]. JAMA Dermatology. doi: 10.1001/jamadermatol.2014.2660.
  9. Ruocco V, Ruocco E, Piccolo V, et al. The immunocompromised district in dermatology: a unifying pathogenic view of the regional immune dysregulation. Clin Dermatol. 2014;32(5):569-576.
  10. Spring P, Spanou Z, de Viragh PA. Lichen planopilaris treated by the peroxisome proliferator activated receptor-γ agonist pioglitazone: lack of lasting improvement or cure in the majority of patients. J Am Acad Dermatol. 2013;69(5):830-832.
  11. Park J, Yun SK, Cho YS, et al. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy. Dermatology. 2014;228(1):37-41.

Disclosure statements are available on the authors' profiles:

Robert Brodell MD, FAAD

Further Reading

Most Read This Week

Recently Updated